Table 3 Clinical parameters
From: Autologous bone marrow-derived mononuclear cell therapy in three patients with severe asthma
Visit (days) | ||||||||
|---|---|---|---|---|---|---|---|---|
Patient | Parameters | D–28 (baseline) | D + 7 | D + 30 | D + 60 | D + 120 | D + 180 | D + 360 |
1 | FVC (L) | 2.23 | 2.18 | 2.04 | 2.06 | 1.87 | 2.05 | 1.89 |
FVC (%) | 76 | 75 | 70 | 70 | 64 | 70 | 65 | |
FEV1, pre-BD (L) | 1.5 | 1.6 | 1.48 | 1.57 | 1.5 | 1.56 | 1.46 | |
FEV1 (%) | 62 | 66 | 61 | 65 | 62 | 65 | 61 | |
6MWT (m) | 273 | 273 | 291 | 276 | 240 | 269 | 294 | |
2 | FVC (L) | 1.99 | 2.00 | 2.40 | 1.72 | 1.78 | 1.85 | 1.77 |
FVC (%) | 74 | 74 | 89 | 64 | 66 | 68 | 66 | |
FEV1, pre-BD (L) | 0.88 | 0.95 | 1.08 | 0.65 | 0.71 | 0.76 | 0.66 | |
FEV1 (%) | 41 | 44 | 50 | 30 | 33 | 35 | 31 | |
6MWT(m) | 412 | * | 380 | 255 | 310 | 176 | 324 | |
3 | FVC (L) | 1.89 | 2.10 | 1.87 | 1.99 | 1.94 | 1.68 | 1.86 |
FVC (%) | 64 | 72 | 64 | 68 | 66 | 57 | 64 | |
FEV1, pre-BD (L) | 0.83 | 0.85 | 0.77 | 0.87 | 0.86 | 0.78 | 0.85 | |
FEV1 (%) | 35 | 36 | 33 | 37 | 37 | 33 | 37 | |
6MWT (m) | 354 | 390 | 380 | 450 | 441 | 360 | 390 | |